anti-BCMA/NKG2DL/FAP TCR T-cell therapy (Guangdong VitaLife)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-BCMA/NKG2DL/FAP TCR T-cell therapy (Guangdong VitaLife)
Drug Alias NameBCMA/NKG2DL/FAP-targeted HLA-independent TCR-T cells
ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionFibroblast activation protein alpha modulatorsTumor necrosis factor ligand superfamily member 13 modulatorsNKG2D ligands modulators
TargetsProlyl endopeptidase FAPTumor necrosis factor ligand superfamily member 13NKG2D ligands
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesGuangdong Vitalife Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangdong Vitalife Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A